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Abstract 
The purpose of our present study was to establish the incidence of UTIs in adult male patients in the Southern region of 
Hungary over a long surveillance period (2008 - 2017). The antimicrobial susceptibility testing was performed using the disk 
diffusion method. Overall, n = 3750 of these outpatient samples (17.73%) and n = 5902 of inpatient samples (30.54%) 
originated from male patients. Members of the Enterobacteriaceae family were the most commonly isolated (outpatient: 64.4%, 
inpatient: 55.57%), with E. coli being the most common urinary pathogen in male patients (outpatient: 37.23%, inpatient: 27.40%), 
followed by Enterococcus spp. (outpatient: 22.72%, inpatient: 23.43%), and P. aeruginosa (outpatient: 7.15%, inpatient: 
9.2%). Between 2010 and 2017, n = 501 (62.65 ± 13.51 per year) extended-spectrum β-lactamase (ESBL) - positive isolates 
were recorded from outpatients and n = 737 (105.28 ± 31.99 per year) from inpatients (p = 0.032). Similarly to other bacterial 
infections, patients affected by drug-resistant urinary pathogens may encounter a poor clinical outcome and complications. 
 
Rezumat 
Scopul studiului prezentat a fost de a stabili incidența infecțiilor de tract urinar (UTI) la pacienții de sex masculin adulți din 
regiunea sudică a Ungariei pe o perioadă lungă de supraveghere (2008 - 2017). Testul de sensibilitate antimicrobiană a fost 
efectuat folosind metoda de difuzie a discului. În ansamblu, 3750 dintre aceste probe au provenit de la pacienți tratați 
ambulator (17,73%) și 5902 de probe de la pacienți internați (30,54%) de sex masculin. Membrii familiei Enterobacteriaceae 
au fost cei mai frecvent izolați patogeni (ambulatoriu: 64,4%, internați: 55,57%), E. coli fiind cel mai frecvent agent patogen 
la pacienții de sex masculin (ambulatoriu: 37,23%, internați: 27,40%), urmat de Enterococcus spp. (ambulatoriu: 22,72%, 
internați: 23,43%) și P. aeruginosa (ambulatoriu: 7,15%, internați: 9,2%). Între 2010 și 2017, 501 (62,65 ± 13,51 pe an) izolate 
ESBL-pozitive au fost înregistrate de la pacienți din ambulator și 737 (105,28 ± 31,99 pe an) de la pacienți internați (p = 0,032). 
În mod similar cu alte infecții bacteriene, pacienții afectați de agenți patogeni rezistenți la medicamente pot avea rezultate 
clinice slabe și pot înregistra diferite complicații. 
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Introduction 
Urinary tract infections (UTIs) are pathologies affecting 
a part of an individual’s urinary system, including the 
bladder, urethra or the kidneys. UTIs are the second 
common type of infections in human medicine, 
representing around 10 - 30% of community-acquired 
and 25 - 50% of nosocomial infections worldwide 
[21, 32, 33, 37]. They are considered as an important 
factor of morbidity and mortality and an important 
economic burden (the medical care of these patients, 
together with the loss of productivity associated with 
UTIs is estimated to cost around 5 billion US$ per 
year) [16, 35]. UTIs may also often correspond to 
serious complications, sequelae, recurrence and decreased 
quality of life (QoL) for the affected patients [15, 
16, 21, 37]. Members of the Enterobacterales order, 
including uropathogenic strains of Escherichia coli 
(UPEC) and Klebsiella pneumoniae (UPKP) are some 
of the most important causes of uncomplicated and 
community-acquired urinary tract infections, in addition 
to Enterococcus spp., Staphylococcus saprophyticus (so-
called “honeymoon cystitis”) and Group B streptococci 
[1, 15, 41]. Nevertheless, causative agents of UTIs in 
nosocomial settings (especially in case of immuno-
compromised patients) may be much more diverse, 
including non-fermenting Gram-negative bacteria, S. 
aureus and fungal species, facilitating the increasing 
occurrence of unconventional urinary pathogens [5, 
10, 12, 15, 36]. 
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The incidence of UTIs differs considerably among 
different patient populations, including different genders, 
age groups and immune status: symptomatic UTI are 
far more common in women than in men. 30 - 50% of 
women experience uncomplicated cystitis at least once 
in their lifetime, while this ratio is around 0.5 - 5% 
for males [21, 23, 24]. In addition, the incidence of 
UTIs in males between 18 - 50 years of age is very 
low (5 - 8 per 10,000 patient/years), compared to the 
sharp increase in incidence over 50 years of age 
[23, 24, 41]. This may be explained by anatomical 
differences between the two sexes (longer urethral 
lengths, the lack of moisture in the periurethral 
environment, antibacterial substances originating from 
the prostatic fluids, less pronounced colonization of the 
urethra by potential urinary pathogens); however, 
symptomatic UTIs in males may be more severe and 
harder to treat [21-24, 41, 44]. Risk factors for males 
include lack of circumcision, anatomical abnormalities, 
having recent urinary procedures, an immunocompromised 
state and high-risk sexual practice [21-24, 41, 44]. 
Although several novel antibiotic agents have been 
approved for clinical use in recent 10 - 15 years, the 
therapy of UTIs (especially in outpatient settings) is 
becoming an important challenge for clinicians, due to 
the rapid development and spread of antimicrobial 
resistance (AMR) [19]. The growing prevalence of 
multidrug-resistant (MDR; i.e. exhibiting resistance to 
at least one agent, in at least three antibiotic categories) 
pathogens in UTIs limit therapeutic options considerably 
[1, 42]. The increasingly common occurrence of extended-
spectrum β-lactamase (ESBL) genes (encoded on 
plasmids) in the members of the Enterobacterales 
order is a cause of considerable worry both for clinicians 
and microbiologists worldwide; ESBLs confer resistance 
to classical penicillin-derivatives, such as broad-spectrum 
cephalosporins, which are all considered safe and 
effective therapeutic alternatives, forcing clinicians to 
utilize agents with a more pronounced toxicity profile 
(i.e. fluoroquinolones, such as ciprofloxacin or amino-
glycosides, such as gentamicin) in the affected 
patients [14]. 
It is commonplace to treat patients with uncomplicated 
UTIs based on empirical antimicrobial therapy (without 
results of microbiological analyses or susceptibility-
testing); nonetheless, decisions on drug therapy may 
also be influenced by social and monetary aspects 
(such as the price of the drugs, drug availability and 
predicted adherence of the patients), drug allergies and 
tolerability of these antibiotics [13]. In outpatient 
cases, publications reporting on local epidemiological 
data are useful to guide therapeutic choices. However, 
there is a lack of data for the epidemiology and resistance 
trends for UTIs of specific patient groups, namely for 
males, children and transplant patients, therefore the 
choice of appropriate empiric antibiotic therapy may 
be hindered by the inability of assess local patterns of 
resistance [23, 43]. Considering all these aspects, the 
aim of this paper was to report on the epidemiology 
and resistance trends of UTIs among adult males in a 
tertiary-care teaching hospital in the Southern region 
of Hungary over a long study period of 10-years. 
 
Materials and Methods 
Study design, data collection methods 
The present study was based on microbiological data 
collected for a 10-year surveillance period (2008.01.01 - 
2017.12.31) at the Institute of Clinical Microbiology 
(University of Szeged, Hungary). The design of the 
study is retrospective. The Institute is the main diagnostic 
laboratory of the Albert Szent-Györgyi Health Centre, 
which is a primary- and tertiary-care teaching hospital 
in Szeged, Hungary. At the time of the study, the 
Centre had a capacity of 1,820-beds (1,465 acute and 
355 chronic beds, respectively), with an annual patient 
turnover of over 400,000 patients in the region, 
according to the data of the Hungarian National Health 
Insurance Fund (NEAK), from general practitioner (GP) 
level care to specialized medical interventions [31]. 
Data for the study was collected by the study authors 
via the MedBakter laboratory system for urine samples 
originating from adult male patients, positive for 
bacterial pathogens. Samples with clinically-relevant 
colony counts (usually 10
5
 < colony forming units 
(CFU)/mL) and bacteria (determined and interpreted 
by considering international guidelines for diagnosing 
UTIs and information supplied on microbiological 
analysis request forms), that were positive for the 
nitrite and leukocyte-esterase tests were included in 
the data for this survey [36]. Only the first isolate per 
patient was included in the study; isolates presenting 
with different antibiotic-susceptibility patterns were 
considered as different individual isolates. Samples 
from female patients and from patients < 18 years of 
age were excluded from data collection. In addition, 
the age of the male patients and inpatient/outpatient 
status were also collected. 
Identification of bacterial isolates 
The cultivation of relevant bacterial isolates was carried 
out using standard bacteriological protocols. 10 µL of 
each un-centrifuged urine sample was cultured on 
various non-selective and selective-differentiating media 
(such as blood agar, eosine methylene blue agar and 
UriSelect chromogenic agar plates (Bio-Rad, Berkeley, 
CA, USA)) with a calibrated loop, according to the 
manufacturer’s instructions; plates were incubated 
at 37°C for 24 - 48 h, aerobically. If the relevant 
pathogens presented in significant colony count, the 
plates went on for further processing. During 2008 - 
2012, standard biochemical assays and the VITEK 2 
Compact ID/AST (bioMérieux, Marcy-l’Étoile, France) 
were used for bacterial identification; from 2013 
onward, this matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS; 
Bruker Daltonics, Bremen, Germany) was also introduced 
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into routine ID practice. The methodology of sample 
preparation for MALDI-TOF MS measurements was 
described previously [12, 36]. MS assays were performed 
by the Microflex MALDI Biotyper (Bruker Daltonics, 
Bremen, Germany); spectrum analysis and ID were 
carried out by the MALDI Biotyper RTC 3.1 soft-
ware (Bruker Daltonics) and the MALDI Biotyper 
Library 3.1. 
Antimicrobial Susceptibility Testing (AST) 
The evaluation of the resistance trends was carried out 
regarding the most prevalent UTI pathogens isolated 
from male patients, namely members of the order of 
Enterobacterales, P. aeruginosa and Enterococcus 
spp. Antimicrobial susceptibility testing (AST) was 
performed by standard disk diffusion methodologies 
on Mueller-Hinton agar plates (Liofilchem, Abruzzo, 
Italy) described by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST), 
including. During AST, the susceptibility to the following 
antibiotics were tested (taking into consideration 
intrinsic resistance of isolates): ampicillin (10 μg), 
amoxicillin/clavulanic acid (20/10 μg), cefuroxime 
(30 μg), ceftriaxone (30 μg), ceftazidime (30 μg), 
piperacillin/tazobactam (30/6 μg), cefepime (30 μg), 
imipenem (10 μg), meropenem (10 μg), ciprofloxacin 
(5 μg), levofloxacin (5 μg), gentamicin (10 μg), amikacin 
(30 μg), trimethoprim-sulfamethoxazole (23.75/1.25 
μg), vancomycin (5 μg) and linezolid (30 μg). The 
interpretation of the results was based on EUCAST 
Clinical Breakpoints 9.0. 
Discrepant results were verified using the VITEK 2 
Compact ID/AST (bioMérieux, Marcy-l’Étoile, France) 
automated system. The following bacterial strains 
were used as quality controls: E. coli ATCC 25922, K. 
pneumoniae ATCC 700603, E. faecalis ATCC 29212 
and S. aureus ATCC 29213. If AST results were 
indicative of ESBL-production among Enterobacterales 
(according to EUCAST recommendations), phenotypic 
detection was performed using ESBL Detection Set 
(MAST Diagnostica GmbH, Reinfeld, Germany) from 
2010 onward, with adherence to manufacturer’s 
instructions [17]. 
Statistical Analysis 
Descriptive statistical analysis, normality tests (Shapiro-
Wilk) and non-parametric tests (Mann-Whitney U test) 
with the SPSS software version 22 (IBM SPSS 
Statistics for Windows 22.0, Armonk, NY, USA, IBM 
Corp.) were used. p values < 0.05 were considered 
statistically significant. 
 
Results and Discussion 
The length of our surveillance study was 10-years, 
starting from 2008 and ending with 2017; in this period, 
the Institute had processed 21,150 positive urine 
samples from outpatient clinics and 19,325 positive 
urine samples from inpatient departments. Overall, 
n = 3750 of these outpatient samples (17.73%) and 
n = 5902 of inpatient samples (30.54%) originated 
from male patients who were 18 years or older at the 
time of sample submission. The sample distribution of 
the positive urine samples for males was the following: 
in outpatients 74.17% was midstream urine, while in 
inpatients 67.30% was catheter-specimen urine. Other 
samples types, such as first-stream urine, suprapubic 
bladder aspiration and urine obtained after a prostate 
massage were less common in both groups (4.01% and 




Sample distribution from the outpatient and inpatient departments over the 10-year period 
 




Age distribution of the affected patients in the outpatient and inpatient groups 
 
The median age of affected patients was 55 years 
(range: 18 - 97) in the outpatient group, while in the 
inpatient group, the median age was 58 years (range: 
18 - 96). In both inpatient and outpatient groups, 
patient aged 56 years or older constituted the over-
whelming majority of patients (78.81% and 84.68%, 
respectively); patients over 70 years presented in the 
highest numbers (42.84% and 43.98%, respectively) 
(Figure 2). 
The species distribution of outpatient and inpatient 
isolates did not present high variance, 36 and 37 
different pathogens were identified on the species-level, 
respectively (Table I and Table II). 72.96% of isolates 
were Gram-negative, 26.0% were Gram-positive, 
0.67% were yeasts and 0.37% were atypical 
bacteria in the out-patient group (Table I). As a 
comparison, 66.88% of urinary pathogens were 
Gram-negative, 26.92% were Gram-positive, 6.15% 
were yeasts and 0.05% were atypical bacteria 
(Table II) in the inpatient group. Species-wise, the 
members of the Enterobacterales family were the 
most commonly isolated (outpatient: 64.4%, inpatient: 
55.57%), with E. coli being the most common urinary 
pathogen in male patients (outpatient: 37.23%, 
inpatient: 27.40%), followed by Enterococcus spp. 
(outpatient: 22.72%, inpatient: 23.43%), and P. 
aeruginosa (outpatient: 7.15%, inpatient: 9.2%) (Table I 
and Table II). 
Table I 
Species-composition of the urinary isolates from outpatient samples, 2008 - 2017 
  Study year    
Isolated species 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 N % 
Achromobacter xylosoxidans                 2   2 0.05 
Acinetobacter baumannii 3 1     2   5 4 2 5 22 0.59 
A. lwoffi 3     1 2 4 2     1 13 0.35 
A. junii   1             1 1 3 0.08 
Burholderia cepacia     3     2         5 0.13 
Candida albicans     2       5 8 2 2 19 0.51 
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  Study year    
Isolated species 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 N % 
C. glabrata       1           1 2 0.05 
C. parapsilosis                 1   1 0.03 
C. tropicalis           2 1       3 0.08 
Citrobacter freundii 1 3 2   2 2       1 11 0.29 
C. koseri 1   1 2 2 5   5 7 8 31 0.83 
Enterobacter asburiae           3 1   1 1 6 0.16 
E. cloacae 3 7 5 5 6 5 3 10 11 9 64 1.71 
E. kobei           1 6 4   2 13 0.35 
Enterococcus faecalis 85 62 60 61 72 68 83 111 100 131 833 22.21 
E. faecium   2   4 3 2   2 1 5 19 0.51 
Escherichia coli 80 63 123 117 111 144 176 196 186 200 1396 37.23 
Klebsiella aerogenes 1 2 3 4 1 2   3 3 8 27 0.72 
K. oxytoca 4   4   5 11 9 11 6 12 62 1.65 
K. pneumoniae 27   74   42 71 39 74 67 90 484 12.91 
Mycoplasma hominis       2             2 0.05 
Morganella morganii     1 2 2 4 1 3 7 4 24 0.64 
Proteus mirabilis 5 4 14 18 18 25 32 38 40 55 249 6.64 
P. vulgaris 3 4 6 2 2 3 5 4 5   34 0.91 
Providencia rettgerii                 1   1 0.03 
P. stuartii                   1 1 0.03 
Pseudomonas aerugnosa 28 25 21 37 25 32 23 24 25 28 268 7.15 
Serratia marcescens   1         1 3 6 1 12 0.32 
Staphylococcus aureus   1   8 8 7 8 8 10 9 59 1.57 
S. saprophyticus         1       3   4 0.11 
S. epidermidis   3 5 1   4         13 0.35 
S. hominis 4 2                 6 0.16 
S. haemolyticus           1         1 0.03 
Stenotrophomonas maltophilia 1     1   2   2 1 1 8 0.21 
Streptococcus agalactiae 5 5 3 2 3 4 2 6 5 5 40 1.07 
Ureaplasma urealyticum 2     2   4 1 1 2   12 0.32 
 
Table II 
Species-composition of the urinary isolates from inpatient samples, 2008 - 2017 
  Study year     
Isolated species 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 N % 
Achromobacter xylosoxidans     1               1 0.02 
Acinetobacter baumannii 2 3 7 3 14 11 8 9 6 5 68 1.15 
A. lwoffi   1           10 2   13 0.22 
A. junii               1     1 0.02 
Burholderia cepacia 8 1 2 4 2 1 2     1 21 0.36 
Candida albicans 10 15 18 8 11 22 33 30 33 60 240 4.07 
C. glabrata 3 4 2 4 2 2 8 20 5 11 61 1.03 
C. parapsilosis   3 1   3 1 2 5   4 19 0.32 
C. krusei     1 2 2 4 2 2 2 4 19 0.32 
C. tropicalis 3   6 1 3 1 2 4   4 24 0.41 
Citrobacter freundii 2   1 1       2 2 2 10 0.17 
C. koseri   2 2 1   5   6 2 5 23 0.39 
Enterobacter asburiae           1         1 0.02 
E. cloacae 9 10 19 9 12 14 14 11 7 8 113 1.91 
E. kobei     1         4 2 4 11 0.19 
Enterococcus faecalis 108 92 95 105 120 142 152 138 161 158 1271 21.54 
E. faecium 5 14 7 7 7 13 13 7 21 18 112 1.90 
Escherichia coli 105 103 142 174 165 164 208 209 192 155 1617 27.40 
Klebsiella aerogenes 3 3 4 6 5 1 4 1 3 2 32 0.54 
K. oxytoca 6 4 6 9 6 9 14 9 15 15 93 1.58 
K. pneumoniae 42 43 73 68 87 72 110 99 117 79 790 13.39 
Mycoplasma hominis       3             3 0.05 
Morganella morganii 3 2 1       3 6 17 5 37 0.63 
Proteus mirabilis 16 20 30 54 44 45 72 79 58 52 470 7.96 
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  Study year     
Isolated species 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 N % 
P. vulgaris 3 6 6 10 7 4 11 4 7 5 63 1.07 
Providencia rettgerii           1   1   4 6 0.10 
P. stuartii               1 3 1 5 0.08 
Pseudomonas aerugnosa 45 65 47 58 76 45 55 46 52 54 543 9.20 
Serratia marcescens 1 1   2 2 1 5 2 1 4 19 0.32 
Staphylococcus aureus 10 13 9 11 9 11 8 6 13 8 98 1.66 
S. saprophyticus 3   1   3 3 2   2 4 18 0.30 
S. epidermidis 6 7   1   3 1   2   20 0.34 
S. hominis 9   2 3 3           17 0.29 
S. haemolyticus           4     2   6 0.10 
S. hominis 9                   9 0.15 
Stenotrophomonas maltophilia   1 1 1   1 4     2 10 0.17 
Streptococcus agalactiae 5 7 3 5 3 4 3 5 1 2 38 0.64 
 
Susceptibility results were collected for the isolates 
that were the most numerous in the adult male patients, 
namely members of the Enterobacteriaceae family, 
Enterococcus spp. and P. aeruginosa (Table III), in 
addition, the distribution of ESBL-producing isolates 
was also assessed over the 8-year period, where data 
was available (2010 - 2017; Figure 3). During our 
study, intrinsic non-susceptibility of relevant bacteria 
was considered during the assessment. The highest 
resistance rates were seen for fluoroquinolones in 
all three groups of uropathogens (Enterobacterales, 
enterococci and P. aeruginosa); additionally, high 
levels of resistance were also shown in regards to 3
rd
 
generation cephalosporins (3GS) and trimethoprim-
sulfamethoxazole in Enterobacterales (e.g., E. coli and 
Klebsiella spp.). For P. aeruginosa, both imipenem and 
meropenem resistance rates were > 10% for out-
patients and > 20% for inpatients. Pronounced differences 
were observed when comparing the resistance levels 
of outpatient and inpatient isolates, in the following 
cases: 3GCs, ciprofloxacin, levofloxacin, gentamicin 
and trimethoprim-sulfamethoxazole-resistance in 
Enterobacterales, ciprofloxacin and levofloxacin resistance 
in Enterococcus spp., and ciprofloxacin, levofloxacin 
and ceftazidime-resistance in P. aeruginosa (Table III). 
Between 2010 and 2017, n = 501 (62.65 ± 13.51 per 
year) ESBL-positive isolates were recorded from 
outpatients and n = 737 (105.28 ± 31.99 per year) 
from inpatients (p = 0.032) (Figure 3). No carbapenem-
resistant isolates in Enterobacterales or vancomycin- 
and linezolid-resistant Enterococcus isolates were 
detected from these samples. 
Table III 
Ratio of resistant isolates among common urinary tract pathogens isolated from male patients over the 10-year 
surveillance period 
  Enterobacteriaceae Enterococcus spp. P. aeruginosa 













Ampicillin 39.85  51.11 n.s.  0.17 0.21  n.s.  - 
Amoxicillin/ 
clavulanic acid 
18.16   20.05 n.s.  0.17 0.21  n.s.  - 
Cefuroxime 25.64  32.18  p = 0.043 - - 
Ceftriaxone 24.91  31.97 p = 0.041  - - 
Ceftazidime 24.86  31.97 p = 0.04  -  11.13 18.81  p = 0.041 
Piperacillin/ 
tazobactam 
 24.86  31.97 p = 0.04   0.17 0.21  n.s.  - 
Cefepime  16.31  19.10 n.s. -  13.56 20.01  n.s. 
Imipenem 0.0  0.0 n.s.  0.03 0.07  n.s.   13.26 24.91    
Meropenem 0.0  0.0 n.s. -  12.50 21.07    
Ciprofloxacin  22.17 34.57   p = 0.029  34.15 19.28  p = 0.019   33.00 43.78  p = 0.039  
Levofloxacin  20.10  31.96  p = 0.31 32.05 17.17   p = 0.022  33.00 43.78  p = 0.039  
Gentamicin  10.17 19.35   p = 0.02 - - 
Amikacin 5.52 7.23  n.s. -  15.56 18.21  n.s. 
Trimethoprim-
sulfamethoxazole  
25.45  36.68   p = 0.03 - - 
Vancomycin - 0.0  0.0 n.s. - 
Linezolid - 0.0  0.0 n.s. - 
*Comparison of resistance levels among isolates originating from outpatients and inpatients; n.s.: not significant 
 




Distribution of ESBL-producing isolates 
 
The principal aim of our research was to provide 
reliable epidemiological information regarding UTIs 
in adult male patients in the southern region of Hungary 
over a long surveillance period, focusing on bacterial 
composition and resistance trends in the most numerous 
isolates. The epidemiology and resistance of urinary 
pathogens from female patients in the geographic 
region has been described previously: in these reports, 
similar resistance trends were observed for the most 
common urinary pathogens [12, 17, 25, 34, 36].  
Nevertheless, the ratio of ESBL-positivity was higher 
in isolates from male patients than in females. The 
data presented here may contribute to the creation of 
a national/transnational surveillance program for male 
UTIs, as previously, international surveillance reports 
(e.g., SENTRY [22, 26], SMART [29], ESGNI-003 
[8], PEP-study [22, 26], MYSTIC [45]) mainly focus 
on data on nosocomial UTIs, affecting both genders. 
In comparison with the already-published data in the 
available literature, our has provided similar conclusions, 
both regarding the species-composition of the relevant 
pathogens (E. coli, K. pneumoniae and Enterococcus, 
which are constituents of the normal intestinal microbiota 
and P. aeruginosa, a common colonizer in nosocomial 
environments) and the prevalence of UTIs in different 
age groups (> 40% of affected patients were over 70 
years of age) [24, 26]. In male patients, the critical 
assessment of the symptoms is important for differential-
diagnostics, as urinary frequency, urgency, dysuria 
and pyuria may also indicate bacterial prostatitis. If 
the symptoms of the patients persist for a long period 
of time, or they are coupled with malaise, myalgia, 
pain from the perineal region, with fever, chills and 
urinary retention, there is a high-risk that the prostate 
is affected (e.g., benign prostate hyperplasia) [19, 24]. 
The development of UTIs in consequence of urinary 
pathogens is dependent on the presence of various 
virulence-determinants, that associated with host 
colonization, tissue invasion and damage, the evasion 
of mucosal immunity and elimination of the host’s 
humoral immune response [4, 6, 15, 32, 33, 38]. The 
abovementioned virulence determinants include protein-
based agents, such as adhesins, toxins, capsule-
production, biofilm (especially in catheter-associated 
infections), siderophore (iron-uptake) systems, lipo-
polysaccharide (LPS), and O- and H-antigens (in select 
Gram-negative bacteria) [4, 6, 15, 32, 33, 38]. Most of 
these are associated with UPEC and UPKP; however, 
the majority may also be found in P. aerugonisa and 
Enterococcus spp. 
Similarly to other bacterial infections, patients affected 
by drug-resistant urinary pathogens may observe a poor 
clinical outcome and complications [3, 27]. Nevertheless, 
with the extensive clinical use of antibiotics, the 
development of bacterial resistance simultaneously and 
inevitably occurs; thus the prudent use of these drugs 
in all settings is of critical relevance [3, 18, 27]. The 
most common pathogens isolated in this study are 
all members of the so-called “ESKAPE” pathogens, 
designated by the World Health Organisation as the 
most important drug resistant bacteria, warranting 
attention from pharmaceutical companies and national 
infection control experts [7, 19, 40]. Trimethoprim-
sulfamethoxazole, fosfomycin and nitrofurantoin (in 
case of E. coli) are regarded as first-choice antibiotics 
in uncomplicated UTIs; while if there are allergies or 
intolerance to these agents, several β-lactam antibiotics 
and fluoroquinolones also offer viable alternatives, 
although the relevance of fluoroquinolones has been 
called into question many times, due to the mounting 
evidence of their serious, debilitating adverse effects 
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[39, 43]. However, it must be noted that if an isolate 
shows resistance to the abovementioned drugs, there 
are essentially no other orally-available options left for 
treat UTIs in the outpatient settings; this is especially 
true in case of P. aeruginosa and enterococci, as the 
list of clinically-useful drugs is already limited in wild-
type strains [4, 14, 21]. There has been renewed 
interest in the acidification of urine and the use of urinary 
disinfectants (e.g., methenamine) to spare antibiotics 
[2, 20]. For Gram-negative bacteria, the presence of β-
lactamases is one of the most significant mechanisms 
of resistance, although alterations in porin channels 
and the cell wall may also lead to resistance for β-
lactam antibiotics [2, 3, 27]. In the Enterobacterales 
order, ESBL-production (sometimes together with 
chromosomally-encoded or plasmid-mediated AmpC-
enzyme production) is an important therapeutic concern; 
since the 21
st
 century, the blaCTX-M-type enzymes have 
become the most prevalent worldwide [9, 11, 14, 28, 
30]. In addition, ESBL-positivity is also alarming 
from the standpoint of infection control, as these genes 
are found on large plasmids or integrons, which may 
include other resistance-determinants, leading to the 
rapid development of MDR in these isolates [11, 
28, 30]. 
Although our study highlight the importance of this 
research field and provides valuable data, several 
limitations of the research methods should be considered: 
the study design was retrospective, and the medical 
records of the individual patients could not be accessed; 
subsequently, the correlation between bacterial isolation 
and other laboratory parameters, signs and symptoms, 
and the immune status of the patients could not be 
assessed. Selection bias is also present for this study 
(similarly to other epidemiological studies from tertiary-
care hospitals), because our data presumably corresponds 
to patients with more severe conditions or under-
lying illnesses. In addition, during laboratory analyses, 
our study did not include the genotypic characterization 
of the causative isolates, such as determination of the 
presence of resistance genes or virulence factors. 
 
Conclusions 
This study presents the epidemiological trends and 
resistance levels of the main urinary pathogens 
associated with urinary tract infections (UTIs) in adult 
males. The study was carried out in the Southern 
region of Hungary over a long surveillance period 
(10 years). In the present study, Gram-negative strains 
were most prevalent in the UTIs of male patients, 
unsurprisingly, E. coli was the most common uro-
pathogen detected. The study also revealed that all the 
major strains showed high levels of resistance against 
fluoroquinolones and in the case of Enterobacteriaceae, 
also for broad-spectrum cephalosporins, due to the 
production of ESBL-enzymes. The renaissance of old 
urinary antibiotics, e.g., nitrofurantoin and fosfomycin 
is warranted. To ensure safe and effective anti-
microbial therapy to treat UTIs (empirically) in male 
patients, the continuous surveillance of causative agents 
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